Register for free to
view the full innovation profile.
This research will be important in the race to cure HIV and acts as an anti-viral that could be used to break down the virus and help a host combat the condition.
About
Background: Anti-retroviral drugs are generally of 5 classes: nucleoside analog reverse transcriptase inhibitors, non-nuclease analog transcriptase inhibitors, protease inhibitors, fusion inhibitors, and integrase inhibitors. There are over 30 commercially available drugs on the market, either of a single class or combination cocktails. While this plethora of drugs would seem adequate, continued drug resistance remains a problem with patients suffering with HIV. Therefore, there remains a need to develop new, improved drugs against retroviruses, particularly HIV. This invention provides additional synthetic nucleoside analogs and their derivatives for further drug development Features and Benefits / Advantages: ♦ Synthetic nucleoside analogs selectively exhibit potent anti-viral activity through inhibition of reverse transcriptase ♦ Synthetic nucleoside analogs remain inert towards mammalian DNA polymerase, resulting in significantly reduced toxicity to host cells ♦ Compounds hold potential as treatments for HTLV III, LAV and/or HBV Stage of Development: Demonstrated inhibition of reverse transcriptase in vitro